Chemical Structure (Duloxetine 01)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 63629-1992
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 63629-1992). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Duloxetine 02)
This is a graphical representation of the proportion of patients with relapse over time from randomization to relapse in days, comparing the treatment of Duloxstine delayed-release capsules versus a placebo. The graph shows that patients who took Duloxstine had a lower proportion of relapse compared to the placebo group.*
Figure 2 (Duloxetine 03)
This appears to be a graph displaying the proportion of patients with relapse over time for two different treatments. The treatments are labeled as "Placebo" and "Duloxeine delayed-release capsules". The x-axis represents the time from randomization to relapse in days, ranging from 0 to 300 days. The y-axis represents the proportion of patients with relapse, ranging from 0 to 1. Unfortunately, without additional context or information, the purpose or meaning of the graph cannot be determined.*
Figure 3 (Duloxetine 04)
Figure 4 (Duloxetine 05)
Figure 5 (Duloxetine 06)
Figure 6 (Duloxetine 07)
Figure 8 (Duloxetine 08)
Figure 9 (Duloxetine 09)
The text represents a chart showing the percentage of patients' improvement and the percentage of improvement in pain from baseline based on two treatments: Placebo and DUL 60 mg taken once daily. The chart shows that for both treatments, there were 8 patients who showed improvement. However, at 100%, DUL had more patients show improvement compared to placebo. The text also shows that there was a steady increase in the percentage of improvement in pain from baseline for patients taking both treatments, with a range of 50 to 100, measured by the BOCF method.*
Figure 10 (Duloxetine 10)
This is a chart that shows the percentage of patients who have experienced improvements in pain levels after taking a placebo or DUL60/120mg once daily. The chart also shows different pain improvement percentages, ranging from 0 to 80. There is no additional information available.*
Label (Lbl636291992)
This is a description of the medication "Duloxetine Delayed-Release Capsules, USP" by NILD. Each capsule contains 60mg of Duloxetine Hydrochloride. It is important to keep this medication out of reach of children and store it between 20° to 25°C (68° to 77°F). The medication should be dispensed in a tight, light-resistant container with a child-resistant closure. The National Drug Code (NDC) number for this medication is 63629-1992-1 and it must be prescribed by a doctor.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
